In principle, prevention strategies, prevention strategies are grouped into three major groups, namely the prevention of the environment, on pejamu, and the milestone. Almost every epidemiolog agree that the most effective prevention for the disease is not contagious health promotion and early detection. Similarly, in breast cancer, the prevention of other forms:
Primary prevention in the primary prevention of breast cancer is one form of health promotion as is done in the "healthy" through efforts to avoid the resignation of keterpaparan on various risk factors and implement healthy lifestyles.
Prevention of secondary made against individuals who have exposed to the risk of breast cancer. Each woman is normal and have normal menstrual cycle is a population at risk of breast cancer. Secondary prevention is done by making early detection. Some methods of early detection continues to progress. Screening through mammografi have claimed accuracy of 90% of all breast cancer sufferer, but keterpaparan continuously on mammografi in healthy women is one of the risk factors, the occurrence of breast cancer.
Therefore, screening with mammografi still can be done with some consideration include:
• Women who have reached the age of 40 years is recommended to do cancer risk assessement survey.
• In women with risk factors to get a referral to mammografi done every year.
• Women normally receive a referral mammografi every 2 years to reach the age of 50 years. Foster and Constanta found that breast cancer mortality by fewer women on the inspection realized (Breast Self-Examination) than not. Although aware of sensitivity to detect breast cancer is only 26%, when combined with mammografi the sensitivity to detect the early to be 75%.
Prevention participations usually directed at individuals who have suffered positive breast cancer. Handling the right people with breast cancer in accordance with stadiumnya will be able to reduce kecatatan and extend life expectancy sufferer. Prevention is an important place to improve the quality of life of people with the disease and prevent complications and to continue treatment.
Actions treatment can be the operation although no effect on the resilience of many people live. When the cancer has bermetastasis far, the action is done with chemotherapy sitostatika. At the stadium, the only form of treatment given simptomatik and are encouraged to seek alternative treatment.
Saturday, November 22, 2008
Treatment breast cancer
There are some cancer treatment breast cancer treatment that implementation depends on many stadium clinic disease (Tjindarbumi, 1994), namely:
Mastektomi Mastektomi is breast operations. There are 3 types of mastektomi (Hirshaut & Pressman, 1992):
Modified Radical Mastectomy, the removal of the entire breast surgery, breast network in the sternum, clavicle and rib bones, and benjolan around the armpit.
Total (Simple) Mastectomy, the removal of the entire breast surgery, but not the glands in the armpit.
Mastectomy serious, the operations part of the breast. Usually referred to as lumpectomy, the removal of the only on the network that contain cancer cells, not the entire breast. This operation is always followed by the provision of radiotherapy. Lumpectomy is usually recommended in patients with large tumornya less than 2 cm and located on the edge of the breast.
Illumination / radiation, the radiation is referred to the process of lighting on the areas affected by cancer by using X-rays and gamma rays, which aims to kill cancer cells remaining in the breast after the operation (Denton, 1996). The effects of this treatment the body to become weak, decreased appetite, the color of the skin around the breast to be black, and Hb and leukosit tend to decline as a result of radiation.
Chemotherapy Chemotherapy is the process of medication in the form of anti-cancer pill or capsule or liquid through Doofus which aims to kill cancer cells. Not only in breast cancer cells, but also in the whole body (Denton, 1996). The effects of chemotherapy patients are experiencing nausea and vomiting and hair fall because of the influence of drugs given during chemotherapy.
Mastektomi Mastektomi is breast operations. There are 3 types of mastektomi (Hirshaut & Pressman, 1992):
Modified Radical Mastectomy, the removal of the entire breast surgery, breast network in the sternum, clavicle and rib bones, and benjolan around the armpit.
Total (Simple) Mastectomy, the removal of the entire breast surgery, but not the glands in the armpit.
Mastectomy serious, the operations part of the breast. Usually referred to as lumpectomy, the removal of the only on the network that contain cancer cells, not the entire breast. This operation is always followed by the provision of radiotherapy. Lumpectomy is usually recommended in patients with large tumornya less than 2 cm and located on the edge of the breast.
Illumination / radiation, the radiation is referred to the process of lighting on the areas affected by cancer by using X-rays and gamma rays, which aims to kill cancer cells remaining in the breast after the operation (Denton, 1996). The effects of this treatment the body to become weak, decreased appetite, the color of the skin around the breast to be black, and Hb and leukosit tend to decline as a result of radiation.
Chemotherapy Chemotherapy is the process of medication in the form of anti-cancer pill or capsule or liquid through Doofus which aims to kill cancer cells. Not only in breast cancer cells, but also in the whole body (Denton, 1996). The effects of chemotherapy patients are experiencing nausea and vomiting and hair fall because of the influence of drugs given during chemotherapy.
Cancer
Disease with the fibrokistik In the women adenosis, fibroadenoma and fibrosis, there is no increased risk of breast cancer occurrence. In hiperplasis and papiloma, slightly increased the risk 1.5 to 2 times. Meanwhile, in the hiperplasia atipik, the risk increased to 5 times.
Obesity There is a positive relationship between body weight and body shape with breast cancer in women post-off. Variations of the frequency of cancer in these countries in West and not the West and frequency changes after the migration indicates that there is the influence of diet on the occurrence of this malignancy.
Consumption of fat consumption is estimated to be fat as a risk factor of the occurrence of breast cancer. Willet et al., Prospective study conducted during the 8 years the consumption of fat and fiber in conjunction with the risk of breast cancer in women age 34 to 59 years old.
Radiation Exposure with ionization radiation during or after the occurrence of pubertas increase the risk of breast cancer. From several studies conducted concluded that the risk of cancer related to radiation dose with the Linear and age when the occurrence of exposure.
Family history and genetic factors, family history is an important component in the history of the screening will be conducted for breast cancer. There is a growing risk of violence in this family of women who suffer breast cancer. In genetic studies found that breast cancer associated with certain genes. When there is a BRCA 1, a suseptibilitas breast cancer genes, the probability for breast cancer is 60% in the age of 50 years and 85% in the age of 70 years.
Obesity There is a positive relationship between body weight and body shape with breast cancer in women post-off. Variations of the frequency of cancer in these countries in West and not the West and frequency changes after the migration indicates that there is the influence of diet on the occurrence of this malignancy.
Consumption of fat consumption is estimated to be fat as a risk factor of the occurrence of breast cancer. Willet et al., Prospective study conducted during the 8 years the consumption of fat and fiber in conjunction with the risk of breast cancer in women age 34 to 59 years old.
Radiation Exposure with ionization radiation during or after the occurrence of pubertas increase the risk of breast cancer. From several studies conducted concluded that the risk of cancer related to radiation dose with the Linear and age when the occurrence of exposure.
Family history and genetic factors, family history is an important component in the history of the screening will be conducted for breast cancer. There is a growing risk of violence in this family of women who suffer breast cancer. In genetic studies found that breast cancer associated with certain genes. When there is a BRCA 1, a suseptibilitas breast cancer genes, the probability for breast cancer is 60% in the age of 50 years and 85% in the age of 70 years.
Risk Factors
According to the Risk Factors Moningke specific breast cancer is still not known, but there are many factors which is estimated to have contributed to the occurrence of breast cancer are:
Reproductive Characteristics of reproductive factors associated with the occurrence of breast cancer risk is nuliparitas, young age at menarche, off in the older age, pregnancy and the first in the age old. The main risk of breast cancer is increasing age. It is estimated, the period between the first occurrence of menstruation at the age of first pregnancy is a window of the initiation of breast cancer. The anatomy and functional, the breast will atrofi with increasing age. Less than 25% of breast cancers occur in the period before the off so early is estimated to cause tumors occur long before the occurrence of clinical changes.
The use of hormones, hormone exogen associated with the occurrence of breast cancer. Reports from the Harvard School of Public Health states that there is an increase of breast cancer, which means the users of estrogen replacement therapy. A metaanalisis stated that although there is no risk of breast cancer in the oral contraceptive users, women who use this drug for a long time have a higher risk for cancer experienced this before off.
Reproductive Characteristics of reproductive factors associated with the occurrence of breast cancer risk is nuliparitas, young age at menarche, off in the older age, pregnancy and the first in the age old. The main risk of breast cancer is increasing age. It is estimated, the period between the first occurrence of menstruation at the age of first pregnancy is a window of the initiation of breast cancer. The anatomy and functional, the breast will atrofi with increasing age. Less than 25% of breast cancers occur in the period before the off so early is estimated to cause tumors occur long before the occurrence of clinical changes.
The use of hormones, hormone exogen associated with the occurrence of breast cancer. Reports from the Harvard School of Public Health states that there is an increase of breast cancer, which means the users of estrogen replacement therapy. A metaanalisis stated that although there is no risk of breast cancer in the oral contraceptive users, women who use this drug for a long time have a higher risk for cancer experienced this before off.
Clinical symptoms
Clinical symptoms of clinical symptoms of breast cancer can be benjolan
• Generally, the breast form that is not benjolan pain in the breast. Benjolan was initially small, the longer the larger, and adheres to the skin or cause changes in the skin of the breast or nipple.
• erosion or eczema nipple Skin or nipple was becoming interested in (retraksi), pink or brownish-kecoklat to become oedema to the skin look like orange leather (peau d'orange), contract, or arising ulcer (ulkus) on the breast. Ulcer that the longer the increasingly large and deep that it can destroy the entire breast, often smelly, and easy bleeding.
• bleeding in the nipple.
• Pain or pain generally arise if a new tumor is large, has emerged sore, or if there is metastase to the bone-bone.
• Then arise lymph gland enlargement in the armpit, swelling (ederma) on the arm, and the spread of cancer throughout the body (Handoyo, 1990). Breast cancer is more easily identified with know Heagensen criteria operbilitas as follows:
• ederma there are broad in the breast skin (about 1 / 3 wide leather breast);
• nodul satellite on the skin of the breast;
• type of breast cancer mastitis karsinimatosa;
• there is a model parasternal ;
• there nodul supraklavikula;
• ederma of arms;
• the metastase far;
• and there are two of the signs Locally advanced, namely ulserasi skin, ederma skin, skin terfiksasi on the wall toraks, lymph gland aksila more than 2.5 cm in berdiameter , And lymph gland aksila cohere
• Generally, the breast form that is not benjolan pain in the breast. Benjolan was initially small, the longer the larger, and adheres to the skin or cause changes in the skin of the breast or nipple.
• erosion or eczema nipple Skin or nipple was becoming interested in (retraksi), pink or brownish-kecoklat to become oedema to the skin look like orange leather (peau d'orange), contract, or arising ulcer (ulkus) on the breast. Ulcer that the longer the increasingly large and deep that it can destroy the entire breast, often smelly, and easy bleeding.
• bleeding in the nipple.
• Pain or pain generally arise if a new tumor is large, has emerged sore, or if there is metastase to the bone-bone.
• Then arise lymph gland enlargement in the armpit, swelling (ederma) on the arm, and the spread of cancer throughout the body (Handoyo, 1990). Breast cancer is more easily identified with know Heagensen criteria operbilitas as follows:
• ederma there are broad in the breast skin (about 1 / 3 wide leather breast);
• nodul satellite on the skin of the breast;
• type of breast cancer mastitis karsinimatosa;
• there is a model parasternal ;
• there nodul supraklavikula;
• ederma of arms;
• the metastase far;
• and there are two of the signs Locally advanced, namely ulserasi skin, ederma skin, skin terfiksasi on the wall toraks, lymph gland aksila more than 2.5 cm in berdiameter , And lymph gland aksila cohere
Stadium cancer
After each faktot T,. N, M is established, the third factor is then merged and acquired stadium cancer as follows:
* Stadium 0: T0 N0 M0
* Stadium 1: T1 N0 M0
* Stadium II A: T0 N1 M0 / T1 N1 M0 / T2 N0 M0
* Stadium II B: T2 N1 M0 / T3 N0 M0
* Stadium III A: T0 N2 M0 / T1 N2 M0 / T2 N2 M0 / T3 N1 M0 / T2 N2 M0
* Stadium III B: T4 N0 M0 / T4 N1 M0 / T4 N2 M0
* Stadium III C: Each T N3 M0
* IV Stadium: Each Each T-N-M1
* Stadium 0: T0 N0 M0
* Stadium 1: T1 N0 M0
* Stadium II A: T0 N1 M0 / T1 N1 M0 / T2 N0 M0
* Stadium II B: T2 N1 M0 / T3 N0 M0
* Stadium III A: T0 N2 M0 / T1 N2 M0 / T2 N2 M0 / T3 N1 M0 / T2 N2 M0
* Stadium III B: T4 N0 M0 / T4 N1 M0 / T4 N2 M0
* Stadium III C: Each T N3 M0
* IV Stadium: Each Each T-N-M1
In breast cancer, TNM assessment as follows:
In breast cancer, TNM assessment as follows:
• T (tumor size), the size of the tumor:
T * 0: not found the primary tumor
T * 1: the size of the tumor diameter of 2 cm or less
* Q 2: the size of the tumor diameter of between 2-5 cm
* Q 3: diameter of the tumor size> 5 cm
* Q 4: does the size of tumors, but there is the spread to the skin or chest wall or both, can be a sore, ederma or swelling, skin redness or a breast benjolan small skin tumors outside the main
• N (node), the regional lymph glands (KGB):
N * 0: there is no Metastasis in the armpit at the regional KGB / aksilla
N * 1: there Metastasis to the KGB aksilla that can still be moved
N * 2: there Metastasis to the KGB aksilla difficult moved
N * 3: there Metastasis to the KGB in the clavicle (supraclavicula) or the KGB in the mammary International in the bone near the sternum
• M (Metastasis), the spread of far:
* M x: Metastasis far can not be assessed
* M 0: there is not much Metastasis
M * 1: there are far Metastasis
• T (tumor size), the size of the tumor:
T * 0: not found the primary tumor
T * 1: the size of the tumor diameter of 2 cm or less
* Q 2: the size of the tumor diameter of between 2-5 cm
* Q 3: diameter of the tumor size> 5 cm
* Q 4: does the size of tumors, but there is the spread to the skin or chest wall or both, can be a sore, ederma or swelling, skin redness or a breast benjolan small skin tumors outside the main
• N (node), the regional lymph glands (KGB):
N * 0: there is no Metastasis in the armpit at the regional KGB / aksilla
N * 1: there Metastasis to the KGB aksilla that can still be moved
N * 2: there Metastasis to the KGB aksilla difficult moved
N * 3: there Metastasis to the KGB in the clavicle (supraclavicula) or the KGB in the mammary International in the bone near the sternum
• M (Metastasis), the spread of far:
* M x: Metastasis far can not be assessed
* M 0: there is not much Metastasis
M * 1: there are far Metastasis
Breast cancer
Breast cancer is breast cancer on the network. This is the most common type of cancer that women suffer. Men can also contract breast cancer, although the probability is smaller than 1 in 1000. The most common treatment is surgery and, if necessary followed by chemotherapy and radiation.
Cancer is a condition in which cells have lost control and the normal mechanisms, so that growth is not normal, fast and not restrained. (http://www.mediasehat.com/utama07.php)
Breast cancer (Carcinoma mammae) is a malignant disease that neoplasma derived from the parenchyma. This disease by Word Health Organization (WHO) to be included in the International Classification of Diseases (ICD) with the code number 17 (http://www.tempo.co.id/medika/arsip/082002/pus-3.htm
Patofisiologi
Tuesday transformation-formed cancer cells from normal cells in a complex process called transformation, which consists of the initiation and promotion phase.
at the initiation stage occurs a change in the genetic material of cells that provoke the cells to become malignant. Changes in the genetic material of cells is caused by an agent called Carcinogen, which can form chemicals, viruses, radiation (irradiation) or sunlight.
but not all cells have the same sensitivity to a Carcinogen. aberration in the genetic material of cells or other called promoter, causing the cells more vulnerable to a Carcinogen. even physical interference menahunpun can make cells become more sensitive to experience a malignancy.
on the stage of the campaign, a cell that has experienced a change initiatives will become malignant.
Cells not pass through initiation stage will not be affected by the campaign. because it required several factors to the occurrence of violence (a combination of the sensitive cells and a Carcinogen).
Stadium Stadium cancer is a disease condition results from a doctor diagnose a disease when the cancer patient who suffered, is the extent to which the level of the spread of cancer is better to the organ or tissue around and far into the spread of the Stadium is only known in the malignant tumor or cancer and not in the tumor tame.
To determine a stadium, should be conducted clinical examination and inspection by the other supporting histopatologi or PA, X-rays, USG, and, if possible with the CT scan, etc. scintigrafi. Many ways to determine the stadium, but for many the most current stadium cancer is based on the TNM classification system recommended by the UICC (International Union Against Cancer from the WHO or the World Health Organization) / AJCC (American Joint Committee on cancer sponsored by the American Cancer Society and the American College of Surgeons).
In the TNM system of assessed three main factors, namely "Q", namely tumor size or tumor size, "N", namely node or regional lymph glands and "M" Metastasis is the spread or distant. The third factor Q, N, M votes either be done before clinical operations, also conducted after the operation and inspection histopatologi (PA)
Cancer is a condition in which cells have lost control and the normal mechanisms, so that growth is not normal, fast and not restrained. (http://www.mediasehat.com/utama07.php)
Breast cancer (Carcinoma mammae) is a malignant disease that neoplasma derived from the parenchyma. This disease by Word Health Organization (WHO) to be included in the International Classification of Diseases (ICD) with the code number 17 (http://www.tempo.co.id/medika/arsip/082002/pus-3.htm
Patofisiologi
Tuesday transformation-formed cancer cells from normal cells in a complex process called transformation, which consists of the initiation and promotion phase.
at the initiation stage occurs a change in the genetic material of cells that provoke the cells to become malignant. Changes in the genetic material of cells is caused by an agent called Carcinogen, which can form chemicals, viruses, radiation (irradiation) or sunlight.
but not all cells have the same sensitivity to a Carcinogen. aberration in the genetic material of cells or other called promoter, causing the cells more vulnerable to a Carcinogen. even physical interference menahunpun can make cells become more sensitive to experience a malignancy.
on the stage of the campaign, a cell that has experienced a change initiatives will become malignant.
Cells not pass through initiation stage will not be affected by the campaign. because it required several factors to the occurrence of violence (a combination of the sensitive cells and a Carcinogen).
Stadium Stadium cancer is a disease condition results from a doctor diagnose a disease when the cancer patient who suffered, is the extent to which the level of the spread of cancer is better to the organ or tissue around and far into the spread of the Stadium is only known in the malignant tumor or cancer and not in the tumor tame.
To determine a stadium, should be conducted clinical examination and inspection by the other supporting histopatologi or PA, X-rays, USG, and, if possible with the CT scan, etc. scintigrafi. Many ways to determine the stadium, but for many the most current stadium cancer is based on the TNM classification system recommended by the UICC (International Union Against Cancer from the WHO or the World Health Organization) / AJCC (American Joint Committee on cancer sponsored by the American Cancer Society and the American College of Surgeons).
In the TNM system of assessed three main factors, namely "Q", namely tumor size or tumor size, "N", namely node or regional lymph glands and "M" Metastasis is the spread or distant. The third factor Q, N, M votes either be done before clinical operations, also conducted after the operation and inspection histopatologi (PA)
Friday, June 27, 2008
Identify Key Drugs and Companies Involved in the Breast Cancer Pipeline with This New Pipeline Insight
DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/14de03/pipeline_insight) has announced the addition of the "Pipeline Insight: Breast Cancer - Recent Approvals Increase Pressure On Pipeline Candidates" report to their offering.
Introduction
Incidence of breast cancer in the seven major markets will total 455,000 in 2008, while 115,000 women will die from the disease. Despite advances in treatment over the past decade, significant unmet needs remain. This level of demand and the large patient potential make breast cancer a relatively attractive indication for drug developers.
Scope
Examination of the breast cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates
Seven major pharmaceutical sales forecasts for Phase III pipeline products through to 2017 with product-specific assumptions
Segmentation and analysis of the current breast cancer pipeline by developmental phase, drug class, company and indication
Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
Report Highlights
There are 121 drugs in clinical development for breast cancer. Molecular targeted therapies are the predominant therapy class in the breast cancer pipeline, accounting for 50% of the pipeline. Cytotoxic therapies account for 25% of the pipeline, while therapeutic vaccines account for 13%, and endocrine therapies account for just 6% of the pipeline.
Seven drugs are in late-phase development for breast cancer, of which four are molecular targeted therapies. Collectively, the late-phase pipeline candidates are forecast to achieve $2,230m in sales in 2017 in the seven major pharmaceutical markets. The late-phase molecular targeted therapies account for the majority of this with sales of $2,142m.
The majority (82%) of clinical trials of drugs in late-phase development for breast cancer are in the metastatic setting. This reflects the higher level of unmet need, lower bar to market entry and shorter trial completion time as compared with the adjuvant or neoadjuvant treatment setting.
Reasons to Purchase
Identify key drugs and companies involved in the breast cancer pipeline based on sales forecasts to 2017 and drug assessment
Understand what the key hurdles to commercial and clinical success are for drugs in late-phase development for breast cancer
Characterize unmet need and poorly served patient subsets within breast cancer and assess the potential for pipeline products to provide satisfaction
Key Topics Covered:
* ABOUT US HEALTHCARE
* EXECUTIVE SUMMARY
* PIPELINE OVERVIEW AND DYNAMICS
* BREAST CANCER - MARKET POTENTIAL
* R&D APPROACH
* CYTOTOXIC THERAPIES ANALYSIS AND FORECASTS
* ENDOCRINE THERAPIES ANALYSIS AND FORECASTS
* MOLECULAR TARGETED THERAPIES ANALYSIS AND FORECASTS
* IMMUNOTHERAPIES AND GENE THERAPIES
* APPENDIX
For more information visit http://www.researchandmarkets.com/research/14de03/pipeline_insight
Introduction
Incidence of breast cancer in the seven major markets will total 455,000 in 2008, while 115,000 women will die from the disease. Despite advances in treatment over the past decade, significant unmet needs remain. This level of demand and the large patient potential make breast cancer a relatively attractive indication for drug developers.
Scope
Examination of the breast cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates
Seven major pharmaceutical sales forecasts for Phase III pipeline products through to 2017 with product-specific assumptions
Segmentation and analysis of the current breast cancer pipeline by developmental phase, drug class, company and indication
Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
Report Highlights
There are 121 drugs in clinical development for breast cancer. Molecular targeted therapies are the predominant therapy class in the breast cancer pipeline, accounting for 50% of the pipeline. Cytotoxic therapies account for 25% of the pipeline, while therapeutic vaccines account for 13%, and endocrine therapies account for just 6% of the pipeline.
Seven drugs are in late-phase development for breast cancer, of which four are molecular targeted therapies. Collectively, the late-phase pipeline candidates are forecast to achieve $2,230m in sales in 2017 in the seven major pharmaceutical markets. The late-phase molecular targeted therapies account for the majority of this with sales of $2,142m.
The majority (82%) of clinical trials of drugs in late-phase development for breast cancer are in the metastatic setting. This reflects the higher level of unmet need, lower bar to market entry and shorter trial completion time as compared with the adjuvant or neoadjuvant treatment setting.
Reasons to Purchase
Identify key drugs and companies involved in the breast cancer pipeline based on sales forecasts to 2017 and drug assessment
Understand what the key hurdles to commercial and clinical success are for drugs in late-phase development for breast cancer
Characterize unmet need and poorly served patient subsets within breast cancer and assess the potential for pipeline products to provide satisfaction
Key Topics Covered:
* ABOUT US HEALTHCARE
* EXECUTIVE SUMMARY
* PIPELINE OVERVIEW AND DYNAMICS
* BREAST CANCER - MARKET POTENTIAL
* R&D APPROACH
* CYTOTOXIC THERAPIES ANALYSIS AND FORECASTS
* ENDOCRINE THERAPIES ANALYSIS AND FORECASTS
* MOLECULAR TARGETED THERAPIES ANALYSIS AND FORECASTS
* IMMUNOTHERAPIES AND GENE THERAPIES
* APPENDIX
For more information visit http://www.researchandmarkets.com/research/14de03/pipeline_insight
Six Weeks of Radiation Therapy May Be Unnecessary for Many Breast Cancer Patients
Groundbreaking European study by Dr. Umberto Veronesi proves a single dose of radiation can be equal to the traditional six-week course
SUNNYVALE, Calif.--(BUSINESS WIRE)--Many women with breast cancer may not need six weeks of daily radiation after surgery. This explosive finding was made public at the recent International Society of Intraoperative Radiation Therapy (ISIORT) conference held in Madrid, Spain earlier this month.
A Single Dose of Radiation is Enough
Renowned surgeon Dr. Umberto Veronesi, founder of the European Institute of Oncology, shared for the first time the results of a long-awaited, eight-year randomized trial comparing his breast cancer patients’ response to two types of radiation therapy. The results so far show that women who received breast conserving surgery, followed by a single dose of intraoperative electron-beam radiation therapy (IOERT) at the time of surgery, had an equal chance of survival as women who underwent the surgery, followed by six weeks of post-operative radiation therapy.
These amazing findings demonstrate that the standard radiation regimen for some lumpectomy patients – already expensive, sometimes painful, and very time-consuming – may be unnecessary.
Dr. Veronesi told the cancer specialists attending ISIORT from 21 countries around the world that IOERT has “obvious advantages in terms of overall treatment time, costs, patient comfort, cosmetic results and quality of life.” He continued, “In my opinion, this will become the routine procedure for breast conserving therapy.”
But while IOERT is quickly becoming the protocol for breast cancer radiation therapy in Europe, most American women are unaware this choice even exists. Those that dare to bring the alternative radiation treatment to their doctors’ attention are experiencing resistance from hospitals unwilling to even investigate the life-saving devices that administer this treatment.
Arleen’s Story
Arleen Sharwell, a breast cancer patient from Long Island, New York, did what all women do: she went to a local breast surgeon for a treatment recommendation. Arleen was told she needed a lumpectomy to remove the tumor, followed by five-to-six weeks of radiation therapy. Having heard about IOERT, Arleen asked if she was a candidate for a single-dose radiation treatment. Her doctor flatly refused to investigate – or to give Arleen a referral to a hospital that did offer such a treatment.
The sad truth is that while more than twenty centers around the world are actively engaged in such a program for their patients, only one hospital in North America currently offers single-dose IOERT treatments for breast cancer: The University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina.
Arleen reached out to UNC doctors Joel Tepper, professor and former chair of radiation oncology, and David Ollila, associate professor and surgical director for the multidisciplinary breast program and multidisciplinary melanoma program. Dr. Tepper and Dr. Ollila immediately recognized that Arleen was a candidate for the single-dose, single-day lumpectomy and IOERT treatment. To Arleen’s delight, her entire breast cancer treatment was completed in one day.
About IOERT
IOERT is the process of delivering a very effective dose of electron-beam radiation to cancer patients during surgery. Hospitals all over the world are discovering innovative applications for the procedure, for virtually every type of cancer. The benefits of IOERT for patients are numerous. By pinpointing the exact area that requires radiation, doctors can deliver a direct dose to affected tissue without passing through the surrounding healthy organs and harming them. For breast cancer patients like Arleen, this often means a single dose of radiation, followed by reconstruction, in a single surgery.
The only FDA-approved device available in North America that is capable of delivering the IOERT treatment extolled by Dr. Veronesi in an unshielded operating room is IntraOp’s Mobetron. The Mobetron is the first fully portable, self-shielded linear accelerator that can be used in an existing operating room.
In addition to their breast cancer program, the University of North Carolina Lineberger Comprehensive Cancer Center uses the Mobetron to deliver IOERT to more than ten different types of cancer. There are four additional hospitals in the US that own the Mobetron and are planning on adding a breast cancer protocol to their ongoing IOERT program.
What Women Need to Know
“I know how difficult accepting a breast cancer diagnosis can be,” said Arleen Sharwell. “However, I can’t stress enough how crucial it is to do your research. When I found the treatment option that I knew was best for me, I refused to let my doctor tell me no. My persistence paid off when I connected with the doctors at UNC and got the single-dose, single-day IOERT treatment I wanted.”
President and CEO of IntraOp, John Powers, echoes Arleen’s sentiment. “Women need to know that they do not have to suffer through six weeks of standard, daily radiation treatment. IOERT can help them get through this terrifying time in their lives much more quickly.”
In IOERT treatment, the skin is protected at all times, preventing it from receiving any of the damage associated with prolonged radiation therapy. Because of this, patients who receive IOERT for cancer treatment also enjoy better cosmetic results. “Three months after surgery, I could hardly tell I had anything done. You would have thought I had plastic surgery,” Arleen said.
“IOERT has been a very viable radiation therapy option for years that may now get the needed recognition with the release of Dr. Veronesi’s randomized trial results,” Dr. Ollila noted. “We have been performing single-dose IOERT for breast cancer patients for more than four years now and feel that it is a viable option for patients seeking to save the breast with minimal radiation exposure."
For additional information on Dr. Veronesi’s study, single-dose IOERT and the Mobetron, please visit the resources page of the IntraOp website.
About IntraOp
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively – for all cancer patients. The company’s flagship product, the Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use the Mobetron as a vital part of their comprehensive cancer program.
For more information about IntraOp Medical and the Mobetron, please visit: www.intraopmedical.com
SUNNYVALE, Calif.--(BUSINESS WIRE)--Many women with breast cancer may not need six weeks of daily radiation after surgery. This explosive finding was made public at the recent International Society of Intraoperative Radiation Therapy (ISIORT) conference held in Madrid, Spain earlier this month.
A Single Dose of Radiation is Enough
Renowned surgeon Dr. Umberto Veronesi, founder of the European Institute of Oncology, shared for the first time the results of a long-awaited, eight-year randomized trial comparing his breast cancer patients’ response to two types of radiation therapy. The results so far show that women who received breast conserving surgery, followed by a single dose of intraoperative electron-beam radiation therapy (IOERT) at the time of surgery, had an equal chance of survival as women who underwent the surgery, followed by six weeks of post-operative radiation therapy.
These amazing findings demonstrate that the standard radiation regimen for some lumpectomy patients – already expensive, sometimes painful, and very time-consuming – may be unnecessary.
Dr. Veronesi told the cancer specialists attending ISIORT from 21 countries around the world that IOERT has “obvious advantages in terms of overall treatment time, costs, patient comfort, cosmetic results and quality of life.” He continued, “In my opinion, this will become the routine procedure for breast conserving therapy.”
But while IOERT is quickly becoming the protocol for breast cancer radiation therapy in Europe, most American women are unaware this choice even exists. Those that dare to bring the alternative radiation treatment to their doctors’ attention are experiencing resistance from hospitals unwilling to even investigate the life-saving devices that administer this treatment.
Arleen’s Story
Arleen Sharwell, a breast cancer patient from Long Island, New York, did what all women do: she went to a local breast surgeon for a treatment recommendation. Arleen was told she needed a lumpectomy to remove the tumor, followed by five-to-six weeks of radiation therapy. Having heard about IOERT, Arleen asked if she was a candidate for a single-dose radiation treatment. Her doctor flatly refused to investigate – or to give Arleen a referral to a hospital that did offer such a treatment.
The sad truth is that while more than twenty centers around the world are actively engaged in such a program for their patients, only one hospital in North America currently offers single-dose IOERT treatments for breast cancer: The University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina.
Arleen reached out to UNC doctors Joel Tepper, professor and former chair of radiation oncology, and David Ollila, associate professor and surgical director for the multidisciplinary breast program and multidisciplinary melanoma program. Dr. Tepper and Dr. Ollila immediately recognized that Arleen was a candidate for the single-dose, single-day lumpectomy and IOERT treatment. To Arleen’s delight, her entire breast cancer treatment was completed in one day.
About IOERT
IOERT is the process of delivering a very effective dose of electron-beam radiation to cancer patients during surgery. Hospitals all over the world are discovering innovative applications for the procedure, for virtually every type of cancer. The benefits of IOERT for patients are numerous. By pinpointing the exact area that requires radiation, doctors can deliver a direct dose to affected tissue without passing through the surrounding healthy organs and harming them. For breast cancer patients like Arleen, this often means a single dose of radiation, followed by reconstruction, in a single surgery.
The only FDA-approved device available in North America that is capable of delivering the IOERT treatment extolled by Dr. Veronesi in an unshielded operating room is IntraOp’s Mobetron. The Mobetron is the first fully portable, self-shielded linear accelerator that can be used in an existing operating room.
In addition to their breast cancer program, the University of North Carolina Lineberger Comprehensive Cancer Center uses the Mobetron to deliver IOERT to more than ten different types of cancer. There are four additional hospitals in the US that own the Mobetron and are planning on adding a breast cancer protocol to their ongoing IOERT program.
What Women Need to Know
“I know how difficult accepting a breast cancer diagnosis can be,” said Arleen Sharwell. “However, I can’t stress enough how crucial it is to do your research. When I found the treatment option that I knew was best for me, I refused to let my doctor tell me no. My persistence paid off when I connected with the doctors at UNC and got the single-dose, single-day IOERT treatment I wanted.”
President and CEO of IntraOp, John Powers, echoes Arleen’s sentiment. “Women need to know that they do not have to suffer through six weeks of standard, daily radiation treatment. IOERT can help them get through this terrifying time in their lives much more quickly.”
In IOERT treatment, the skin is protected at all times, preventing it from receiving any of the damage associated with prolonged radiation therapy. Because of this, patients who receive IOERT for cancer treatment also enjoy better cosmetic results. “Three months after surgery, I could hardly tell I had anything done. You would have thought I had plastic surgery,” Arleen said.
“IOERT has been a very viable radiation therapy option for years that may now get the needed recognition with the release of Dr. Veronesi’s randomized trial results,” Dr. Ollila noted. “We have been performing single-dose IOERT for breast cancer patients for more than four years now and feel that it is a viable option for patients seeking to save the breast with minimal radiation exposure."
For additional information on Dr. Veronesi’s study, single-dose IOERT and the Mobetron, please visit the resources page of the IntraOp website.
About IntraOp
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively – for all cancer patients. The company’s flagship product, the Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use the Mobetron as a vital part of their comprehensive cancer program.
For more information about IntraOp Medical and the Mobetron, please visit: www.intraopmedical.com
Mira Women's Imaging to Open in Harrison State-of-the-Art Technology to be Utilized in a Soothing Environment
Mira Women's Imaging is scheduled to open in Harrison on June 23, 2008, under the direction of founder and director Dr. Catherine Giess. Dr. Giess will focus on the earliest possible detection of breast cancer by utilizing state-of-the-art imaging in Mira's personalized, supportive setting.
Harrison, NY (PRWEB) May 30, 2008 -- Mira Women's Imaging is scheduled to open in Harrison on June 23, 2008, under the direction of founder and director Dr. Catherine Giess. Dr. Giess will focus on the earliest possible detection of breast cancer by utilizing state-of-the-art imaging in Mira's personalized, supportive setting.
All procedures offered at Mira, including digital mammography, breast ultrasound, vacuum-assisted stereotactic and ultrasound guided needle biopsy, will utilize state-of-the-art equipment. A DXA machine, which measures bone mineral density, will be used to identify patients at risk for osteoporosis. Additionally, lateral views of the spine will be used to identify previously unsuspected vertebral fractures, aiding in assessment for future fracture risk.
It is our goal to make our patients' experience as stress-free and comfortable as possible so that they maintain a regular regimen of breast care
Mira Women's Imaging will also offer galactography; ultrasound guided aspiration; needle localizations; and second opinion consultations.
"Digital mammography offers many benefits over traditional film-screen mammography" said Dr. Giess. "The technology is particularly well-suited to women with dense breast tissue."
In its 3,468-square-foot space, Mira offers a serene, personalized environment to help women feel relaxed before, during and after mammography. While they wait, women can sit on cushioned chairs while sipping spring water or gourmet coffee. Features of the private inner waiting area include a water wall and soothing music. Dressing rooms and consultation rooms are highly private.
"It is our goal to make our patients' experience as stress-free and comfortable as possible so that they maintain a regular regimen of breast care," Dr. Giess added.
In addition to establishing Mira Women's Imaging, Dr. Giess is on staff at the Cancer Center of St. Vincent's Catholic Medical Center in Manhattan. Most recently, she served as co-director of breast imaging at Hudson Valley Radiology Associates in Rockland County, where she specialized in breast imaging and diagnostic procedures. Well-respected in her field, Dr. Giess has published numerous scientific articles in peer-reviewed publications and is frequently consulted for her expertise in breast imaging.
Mira Women's Imaging is located at 600 Mamaroneck Ave., Suite 102, Harrison, NY 10528. For additional information, call 914.468.1000 or visit www.mirawomensimaging.com.
About Mira Women's Imaging: Mira Women's Imaging is a state-of-the-art breast health facility offering mammography, breast ultrasound, DXA scans, and diagnostic care in a setting that is comfortable and private. Founder and director Dr. Catherine Giess is a fellowship-trained radiologist and a regional breast health expert with over 12 years of clinical experience in breast imaging and minimally-invasive diagnostic procedures. For more information, visit www.mirawomensimaging.com.
Harrison, NY (PRWEB) May 30, 2008 -- Mira Women's Imaging is scheduled to open in Harrison on June 23, 2008, under the direction of founder and director Dr. Catherine Giess. Dr. Giess will focus on the earliest possible detection of breast cancer by utilizing state-of-the-art imaging in Mira's personalized, supportive setting.
All procedures offered at Mira, including digital mammography, breast ultrasound, vacuum-assisted stereotactic and ultrasound guided needle biopsy, will utilize state-of-the-art equipment. A DXA machine, which measures bone mineral density, will be used to identify patients at risk for osteoporosis. Additionally, lateral views of the spine will be used to identify previously unsuspected vertebral fractures, aiding in assessment for future fracture risk.
It is our goal to make our patients' experience as stress-free and comfortable as possible so that they maintain a regular regimen of breast care
Mira Women's Imaging will also offer galactography; ultrasound guided aspiration; needle localizations; and second opinion consultations.
"Digital mammography offers many benefits over traditional film-screen mammography" said Dr. Giess. "The technology is particularly well-suited to women with dense breast tissue."
In its 3,468-square-foot space, Mira offers a serene, personalized environment to help women feel relaxed before, during and after mammography. While they wait, women can sit on cushioned chairs while sipping spring water or gourmet coffee. Features of the private inner waiting area include a water wall and soothing music. Dressing rooms and consultation rooms are highly private.
"It is our goal to make our patients' experience as stress-free and comfortable as possible so that they maintain a regular regimen of breast care," Dr. Giess added.
In addition to establishing Mira Women's Imaging, Dr. Giess is on staff at the Cancer Center of St. Vincent's Catholic Medical Center in Manhattan. Most recently, she served as co-director of breast imaging at Hudson Valley Radiology Associates in Rockland County, where she specialized in breast imaging and diagnostic procedures. Well-respected in her field, Dr. Giess has published numerous scientific articles in peer-reviewed publications and is frequently consulted for her expertise in breast imaging.
Mira Women's Imaging is located at 600 Mamaroneck Ave., Suite 102, Harrison, NY 10528. For additional information, call 914.468.1000 or visit www.mirawomensimaging.com.
About Mira Women's Imaging: Mira Women's Imaging is a state-of-the-art breast health facility offering mammography, breast ultrasound, DXA scans, and diagnostic care in a setting that is comfortable and private. Founder and director Dr. Catherine Giess is a fellowship-trained radiologist and a regional breast health expert with over 12 years of clinical experience in breast imaging and minimally-invasive diagnostic procedures. For more information, visit www.mirawomensimaging.com.
In New Book, Tess Camillo Solves Mysterious Crucifixion of Rock Star
Crucifixion was no way for Cody Crowne to die. Breast cancer or not, nothing is going to stop Tess Camillo from learning who committed the hideous crime. She has outwitted criminals before, and this time will be no exception. Or will it?
Ashland, OR (PRWEB) June 2, 2008 -- Morgan Hunt's feisty breast cancer survivor and amateur detective, Tess Camillo, returns. Despite a mastectomy in "Sticky Fingers," Tess is back to solve another crime and maybe even fall in love in her latest action-packed adventure "Fool on the Hill" (ISBN 9781593500276, Alyson Books, 2008).
Cody Crowne was a major rock star in the 1980s. Now he's a mellow has-been. But someone wants him dead. The morning after Tess Camillo and her friend Lana attend a concert where Cody is the opening act, Tess finds Cody's body crucified in a park. Who could have committed such a ghastly crime? Tess Camillo is determined to find out.
With her loopy housemate, Lana, Tess sets out to unmask a killer. Clues lead Tess and Lana first to the cocktail parties of Hollywood music producers. Then Tess pries information from a deacon's wife at a Fundamentalist church. Even Legoland and a carousel are paid visits in the quest for a killer. Finally, the women face the dark heart responsible for Cody's crucifixion, and in the process, they come close to facing the same fate.
The Tess Camillo mystery series is just beginning. "Fool on the Hill" is the second book, following the suspenseful "Sticky Fingers." Tess is both an assertive and realistic woman with a determination that will make other women cheer her on. Readers will find her a courageous example of confidence in the face of health and relationship struggles.
Morgan Hunt, herself a breast cancer survivor, has written more than just a mystery. Tess Camillo must face a killer, but she must also face her innermost fears. Following recovery from breast cancer, Tess takes a chance on love again, and she gains the confidence to reveal her scars - emotional and physical -- to her new lover. Hunt writes with hope for those diagnosed with breast cancer, not to mention retribution for criminals.
About the Author
Morgan Hunt was raised on the Jersey shore, but after serving in the Navy in Maine and San Diego, she now hides out in the Pacific Northwest. In 2001, she was diagnosed with advanced lobular invasive carcinoma, a particularly dangerous form of breast cancer. She hopes her Tess Camillo mysteries provide both entertainment and hope to other cancer survivors.
"Fool on the Hill: A Tess Camillo Mystery" (ISBN 9781593500276, Alyson Books, 2008) can be purchased through local and online bookstores. For more information, visit www.morganhuntbooks.com. Publicity contact: www.ReaderViews.com. Review copies available upon request.
Ashland, OR (PRWEB) June 2, 2008 -- Morgan Hunt's feisty breast cancer survivor and amateur detective, Tess Camillo, returns. Despite a mastectomy in "Sticky Fingers," Tess is back to solve another crime and maybe even fall in love in her latest action-packed adventure "Fool on the Hill" (ISBN 9781593500276, Alyson Books, 2008).
Cody Crowne was a major rock star in the 1980s. Now he's a mellow has-been. But someone wants him dead. The morning after Tess Camillo and her friend Lana attend a concert where Cody is the opening act, Tess finds Cody's body crucified in a park. Who could have committed such a ghastly crime? Tess Camillo is determined to find out.
With her loopy housemate, Lana, Tess sets out to unmask a killer. Clues lead Tess and Lana first to the cocktail parties of Hollywood music producers. Then Tess pries information from a deacon's wife at a Fundamentalist church. Even Legoland and a carousel are paid visits in the quest for a killer. Finally, the women face the dark heart responsible for Cody's crucifixion, and in the process, they come close to facing the same fate.
The Tess Camillo mystery series is just beginning. "Fool on the Hill" is the second book, following the suspenseful "Sticky Fingers." Tess is both an assertive and realistic woman with a determination that will make other women cheer her on. Readers will find her a courageous example of confidence in the face of health and relationship struggles.
Morgan Hunt, herself a breast cancer survivor, has written more than just a mystery. Tess Camillo must face a killer, but she must also face her innermost fears. Following recovery from breast cancer, Tess takes a chance on love again, and she gains the confidence to reveal her scars - emotional and physical -- to her new lover. Hunt writes with hope for those diagnosed with breast cancer, not to mention retribution for criminals.
About the Author
Morgan Hunt was raised on the Jersey shore, but after serving in the Navy in Maine and San Diego, she now hides out in the Pacific Northwest. In 2001, she was diagnosed with advanced lobular invasive carcinoma, a particularly dangerous form of breast cancer. She hopes her Tess Camillo mysteries provide both entertainment and hope to other cancer survivors.
"Fool on the Hill: A Tess Camillo Mystery" (ISBN 9781593500276, Alyson Books, 2008) can be purchased through local and online bookstores. For more information, visit www.morganhuntbooks.com. Publicity contact: www.ReaderViews.com. Review copies available upon request.
The North American Menopause Society (NAMS) Issues New Recommendations Regarding Management of Breast Cancer Risk in Postmenopausal Women
CLEVELAND--(BUSINESS WIRE)--The North American Menopause Society (NAMS) has just released a supplement to its official journal Menopause to meet the need for current clinical recommendations for managing breast cancer risk in postmenopausal women.
Breast cancer is the most common cancer among women, except for nonmelanoma skin cancers, and is the second leading cause of cancer death for women worldwide. According to the American Cancer Society, 182,460 new cases of invasive breast cancer will be diagnosed in US women in 2008 with 40,930 deaths anticipated. Women living in North America have the highest rate of breast cancer in the world.
“The single most important risk factor for breast cancer is age. The risk of breast cancer increases among women older than 50 years of age who have either atypical hyperplasia or lobular carcinoma in situ, a first-degree family history of breast cancer, and BRCA1 or BRCA2 genetic mutations,” said Victor G. Vogel, MD, MHS, Professor of Medicine and Epidemiology, University of Pittsburgh School of Medicine, Co-Director, University of Pittsburgh Institute Biochemoprevention Program, who served as Guest Editor of the supplement.
“More than 10 million women in North America are at increased risk of breast cancer, and clinicians have an imperative to identify these women and manage their risk appropriately.”
While breast cancer rates have slowly declined for the past 15 years, especially in postmenopausal women aged 55 to 69 years, these decreases were primarily evident for small tumors (≤2 cm) and local and regional disease. Breast cancer mortality rates have also declined, due to earlier detection through screening and more effective treatment options. The impact of screening, however, has likely reached a plateau. Clinicians are now challenged to counsel their high-risk patients who will receive the maximum benefit from chemoprevention with oral medications. Findings from a number of prospective, randomized, controlled trials have established the efficacy of tamoxifen and raloxifene for the prevention of breast cancer in these women.
The best approach to breast cancer risk estimation and management involves collecting comprehensive data on risk factors from all perimenopausal and early postmenopausal women and evaluating that data with an appropriate quantitative risk model. There is evidence to suggest, however, that such assessments are not routinely conducted by all healthcare providers. This special issue provides an overview of the critical findings and issues regarding breast cancer risk and chemopreventive agents to reduce that risk.
“Written by eight specialists in women’s health and cancer, these articles aim to support clinicians who care for adult women, some of whom might be at increased risk for breast cancer and need advice about interventions, where appropriate, to decrease the likelihood that they will develop an invasive breast cancer in their lifetimes,” explained Dr. Vogel.
This educational supplement, designated a continuing medical education activity by NAMS, has been developed according to the policies established in 2004 by the Menopause Editorial Board and the NAMS Board of Trustees. Publication standards are as strict as with any regular issue of the journal, including the same peer-review process. NAMS appreciates the efforts of the authors and the educational grant from Eli Lilly and Company.
The Mission of NAMS, a nonprofit scientific organization, is to promote the health and quality of life of women through an understanding of menopause. The Society’s membership of 2,000 professionals representing a variety of disciplines—including clinical and basic science experts from medicine, nursing, pharmacy, anthropology, sociology, psychology, and complementary/alternative medicine—makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause. (www.menopause.org)
Contacts
McKinney Advertising & Public Relations
Judy Cerne, President & CEO, 216-621-5133
Fax: 216-621-1181
E-mail: jcerne@mckinneyad.com
or
The North American Menopause Society
Pamela P. Boggs, MBA, Director of Education
& Development, 440-442-7658
Fax: 440-442-2660
Breast cancer is the most common cancer among women, except for nonmelanoma skin cancers, and is the second leading cause of cancer death for women worldwide. According to the American Cancer Society, 182,460 new cases of invasive breast cancer will be diagnosed in US women in 2008 with 40,930 deaths anticipated. Women living in North America have the highest rate of breast cancer in the world.
“The single most important risk factor for breast cancer is age. The risk of breast cancer increases among women older than 50 years of age who have either atypical hyperplasia or lobular carcinoma in situ, a first-degree family history of breast cancer, and BRCA1 or BRCA2 genetic mutations,” said Victor G. Vogel, MD, MHS, Professor of Medicine and Epidemiology, University of Pittsburgh School of Medicine, Co-Director, University of Pittsburgh Institute Biochemoprevention Program, who served as Guest Editor of the supplement.
“More than 10 million women in North America are at increased risk of breast cancer, and clinicians have an imperative to identify these women and manage their risk appropriately.”
While breast cancer rates have slowly declined for the past 15 years, especially in postmenopausal women aged 55 to 69 years, these decreases were primarily evident for small tumors (≤2 cm) and local and regional disease. Breast cancer mortality rates have also declined, due to earlier detection through screening and more effective treatment options. The impact of screening, however, has likely reached a plateau. Clinicians are now challenged to counsel their high-risk patients who will receive the maximum benefit from chemoprevention with oral medications. Findings from a number of prospective, randomized, controlled trials have established the efficacy of tamoxifen and raloxifene for the prevention of breast cancer in these women.
The best approach to breast cancer risk estimation and management involves collecting comprehensive data on risk factors from all perimenopausal and early postmenopausal women and evaluating that data with an appropriate quantitative risk model. There is evidence to suggest, however, that such assessments are not routinely conducted by all healthcare providers. This special issue provides an overview of the critical findings and issues regarding breast cancer risk and chemopreventive agents to reduce that risk.
“Written by eight specialists in women’s health and cancer, these articles aim to support clinicians who care for adult women, some of whom might be at increased risk for breast cancer and need advice about interventions, where appropriate, to decrease the likelihood that they will develop an invasive breast cancer in their lifetimes,” explained Dr. Vogel.
This educational supplement, designated a continuing medical education activity by NAMS, has been developed according to the policies established in 2004 by the Menopause Editorial Board and the NAMS Board of Trustees. Publication standards are as strict as with any regular issue of the journal, including the same peer-review process. NAMS appreciates the efforts of the authors and the educational grant from Eli Lilly and Company.
The Mission of NAMS, a nonprofit scientific organization, is to promote the health and quality of life of women through an understanding of menopause. The Society’s membership of 2,000 professionals representing a variety of disciplines—including clinical and basic science experts from medicine, nursing, pharmacy, anthropology, sociology, psychology, and complementary/alternative medicine—makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause. (www.menopause.org)
Contacts
McKinney Advertising & Public Relations
Judy Cerne, President & CEO, 216-621-5133
Fax: 216-621-1181
E-mail: jcerne@mckinneyad.com
or
The North American Menopause Society
Pamela P. Boggs, MBA, Director of Education
& Development, 440-442-7658
Fax: 440-442-2660
Local Members of Susan G. Komen for the Cure Discuss Funding, Access Needs
Breast Cancer Survivors, Activists Head To Capitol Hill to Marshall Support for Comprehensive Cancer Legislation
WASHINGTON--(BUSINESS WIRE)--Members of the Northeast Ohio Affiliate of Susan G. Komen for the Cure traveled to the nation’s capital June 5 to help make the case for more funding for cancer research and access to screening and treatment. During their meetings with Senator Sherrod Brown, and Representatives Dennis Kucinich, Betty Sutton, Steve LaTourette and Ralph Regula, the delegation discussed the need to energize research and the disparities in access to care that exist, particularly in rural and minority communities.
“Thirty five years after our nation declared war on cancer we are still facing a cancer crisis,” said Rosemary Gold, Advocacy Chair. “This week’s push on Capitol Hill should help build momentum for an all-out assault on all cancer.”
The Northeast Ohio delegation joined nearly 300 survivors and activists from 39 states plus the District of Columbia creating a pink wave across over 400 Capitol Hill offices helping to build a foundation of support for comprehensive cancer legislation that will soon be unveiled by Senators Edward Kennedy (D-MA) and Kay Bailey Hutchison (R-TX). Prior to Senator Kennedy’s recent diagnosis of brain cancer, he chaired a hearing of the Senate Health, Education, Labor and Pension committee that discussed the issues addressed by the bill he and Senator Hutchison are crafting.
The Komen delegation reminded members of Congress that despite the many investments and advancements over the past three decades, 40 percent of Americans will be diagnosed with cancer at some point in their lives, including approximately 1.4 million new cases this year alone. Cancer will kill more than a half million people this year – about 1,500 people a day.
They also called on Congress to provide a greater government investment in cancer research, placing an emphasis on early detection, and promoting the discovery and development of biomarkers to detect cancers at the earliest possible stage. In addition, investment should be focused on personalized treatments, so early detection can be as easy as a blood test and treatments as non-invasive as an injection. At the same time, they warned Congress not to lose sight of the gaps in access to the detection and treatment options available today that impact the uninsured, underinsured and rural and minority populations.
“While we should be excited about the opportunities for the future and should do everything in our power to discover and deliver the cures, we have to close the gaps that exist today,” said Ms. Gold. “If we don’t, as the science surges, the gaps will only widen.”
About Susan G. Komen for the Cure Northeast Ohio Affiliate
Since 1994, the Komen Northeast Ohio Affiliate has raised $12 million to provide funding and support to Northeast Ohio agencies working to create a world without breast cancer. The agencies provide mammograms and screening, breast cancer education and ongoing support to women, men, their families and friends. Up to seventy-five percent of the money raised locally funds programs in Northeast Ohio, and the remaining 25 percent helps fund the Susan G. Komen for the Cure National Research Grant Program. Our vision is to create a world without breast cancer.
WASHINGTON--(BUSINESS WIRE)--Members of the Northeast Ohio Affiliate of Susan G. Komen for the Cure traveled to the nation’s capital June 5 to help make the case for more funding for cancer research and access to screening and treatment. During their meetings with Senator Sherrod Brown, and Representatives Dennis Kucinich, Betty Sutton, Steve LaTourette and Ralph Regula, the delegation discussed the need to energize research and the disparities in access to care that exist, particularly in rural and minority communities.
“Thirty five years after our nation declared war on cancer we are still facing a cancer crisis,” said Rosemary Gold, Advocacy Chair. “This week’s push on Capitol Hill should help build momentum for an all-out assault on all cancer.”
The Northeast Ohio delegation joined nearly 300 survivors and activists from 39 states plus the District of Columbia creating a pink wave across over 400 Capitol Hill offices helping to build a foundation of support for comprehensive cancer legislation that will soon be unveiled by Senators Edward Kennedy (D-MA) and Kay Bailey Hutchison (R-TX). Prior to Senator Kennedy’s recent diagnosis of brain cancer, he chaired a hearing of the Senate Health, Education, Labor and Pension committee that discussed the issues addressed by the bill he and Senator Hutchison are crafting.
The Komen delegation reminded members of Congress that despite the many investments and advancements over the past three decades, 40 percent of Americans will be diagnosed with cancer at some point in their lives, including approximately 1.4 million new cases this year alone. Cancer will kill more than a half million people this year – about 1,500 people a day.
They also called on Congress to provide a greater government investment in cancer research, placing an emphasis on early detection, and promoting the discovery and development of biomarkers to detect cancers at the earliest possible stage. In addition, investment should be focused on personalized treatments, so early detection can be as easy as a blood test and treatments as non-invasive as an injection. At the same time, they warned Congress not to lose sight of the gaps in access to the detection and treatment options available today that impact the uninsured, underinsured and rural and minority populations.
“While we should be excited about the opportunities for the future and should do everything in our power to discover and deliver the cures, we have to close the gaps that exist today,” said Ms. Gold. “If we don’t, as the science surges, the gaps will only widen.”
About Susan G. Komen for the Cure Northeast Ohio Affiliate
Since 1994, the Komen Northeast Ohio Affiliate has raised $12 million to provide funding and support to Northeast Ohio agencies working to create a world without breast cancer. The agencies provide mammograms and screening, breast cancer education and ongoing support to women, men, their families and friends. Up to seventy-five percent of the money raised locally funds programs in Northeast Ohio, and the remaining 25 percent helps fund the Susan G. Komen for the Cure National Research Grant Program. Our vision is to create a world without breast cancer.
Walk the Talk: Cape Clogs' Pink Ribbon Clog to Raise Awareness for Breast Cancer Research
Cape Clogs, a leading privately held designer, distributor and marketer of fashion forward Swedish clogs, has launched Clogs for a Cure, a campaign to support breast cancer awareness, driven by its new Pink Ribbon clog. With the purchase of each Pink Ribbon clog, a portion of sales is directed to the National Breast Cancer Foundation. The Pink Ribbon clog is the first in a series of cause-related product launches from Cape Clogs.
Bourne, Mass (PRWEB) June 12, 2008 -- Cape Clogs is proud to announce Clogs for a Cure, a campaign to support breast cancer awareness, driven by its new Pink Ribbon clog. With the purchase of each Pink Ribbon clog, a portion of sales is directed to the National Breast Cancer Foundation, an organization committed to increasing awareness of breast cancer through education and by providing mammograms to those in need. The Pink Ribbon clog is the first in a series of cause-related product launches from Cape Clogs.
"Breast cancer has touched me in a personal way with the loss of my mother. The Pink Ribbon clog was created in her memory for her beautiful courage as an everlasting legacy," said Pamela J. Irving, founder of Cape Clogs. "My hope is that the Pink Ribbon clog will stand as a testament to helping find a cure for this disease."
The Pink Ribbon clog is made of real genuine leather and is adorned with the universally recognized pink ribbon symbol. Cape Clogs feature an alder wood sole and have non-skid bottoms. The comfortable clog is lightweight and good for posture.
The Pink Ribbon clog is available in women sizes 5 to 11 with a suggested retail of $80. The Pink Ribbon clog is available for fundraising opportunities at wholesale costs. For more information on Cape Clogs' Clogs for a Cure, visit www.capeclogs.com/cancer. Images and product samples are available.
Cape Clogs is a leading privately held designer, distributor and marketer of fashion forward Swedish clogs that exude personality and youthful energy with vivid signature prints. Based on Cape Cod, Massachusetts, Cape Clogs offers a wide range of clogs for men, women and children in the work and lifestyles categories. It has established sales distribution in traditional footwear channels, including independent boutiques, uniform suppliers, sporting goods stores, and other retail catalog and website partners. Cape Clogs has an exclusive partnership with Torpatofflen AB, a sixth-generation traditional clog manufacturer located in Småland, Sweden. For a full product catalog or purchasing, visit www.capeclogs.com.
Bourne, Mass (PRWEB) June 12, 2008 -- Cape Clogs is proud to announce Clogs for a Cure, a campaign to support breast cancer awareness, driven by its new Pink Ribbon clog. With the purchase of each Pink Ribbon clog, a portion of sales is directed to the National Breast Cancer Foundation, an organization committed to increasing awareness of breast cancer through education and by providing mammograms to those in need. The Pink Ribbon clog is the first in a series of cause-related product launches from Cape Clogs.
"Breast cancer has touched me in a personal way with the loss of my mother. The Pink Ribbon clog was created in her memory for her beautiful courage as an everlasting legacy," said Pamela J. Irving, founder of Cape Clogs. "My hope is that the Pink Ribbon clog will stand as a testament to helping find a cure for this disease."
The Pink Ribbon clog is made of real genuine leather and is adorned with the universally recognized pink ribbon symbol. Cape Clogs feature an alder wood sole and have non-skid bottoms. The comfortable clog is lightweight and good for posture.
The Pink Ribbon clog is available in women sizes 5 to 11 with a suggested retail of $80. The Pink Ribbon clog is available for fundraising opportunities at wholesale costs. For more information on Cape Clogs' Clogs for a Cure, visit www.capeclogs.com/cancer. Images and product samples are available.
Cape Clogs is a leading privately held designer, distributor and marketer of fashion forward Swedish clogs that exude personality and youthful energy with vivid signature prints. Based on Cape Cod, Massachusetts, Cape Clogs offers a wide range of clogs for men, women and children in the work and lifestyles categories. It has established sales distribution in traditional footwear channels, including independent boutiques, uniform suppliers, sporting goods stores, and other retail catalog and website partners. Cape Clogs has an exclusive partnership with Torpatofflen AB, a sixth-generation traditional clog manufacturer located in Småland, Sweden. For a full product catalog or purchasing, visit www.capeclogs.com.
Dr. Catherine Giess Educates Women at Breast Cancer Fundraiser Prominent breast radiologist addresses early breast cancer detection
Dr. Catherine Giess, founder and director of Harrison-based Mira Women's Imaging, recently addressed more than 120 women, including Sole Ryeders & Friends, at the Wainwright House in Rye about breast cancer. Sole Ryeders & Friends, which was established in Rye, NY, is a team of women who will participate in the 40-mile Avon Walk for Breast Cancer in October for the second consecutive year.
Harrison and Rye, NY (PRWEB) June 18, 2008 -- Dr. Catherine Giess, founder and director of Harrison-based Mira Women's Imaging, recently addressed more than 120 women, including Sole Ryeders & Friends, at the Wainwright House in Rye about breast cancer. Sole Ryeders & Friends, which was established in Rye, NY, is a team of women who will participate in the 40-mile Avon Walk for Breast Cancer in October for the second consecutive year.
More than 120 women attended the "Wisdom & Wine" Breast Cancer Awareness Fundraiser, where they learned about the different stages of breast cancer and corresponding survival rates; breast cancer risk factors; signs of breast cancer on mammography, ultrasound and MRI; the benefits of digital mammography; biopsy techniques; breast pain and lumps; the breast cancer gene; proactive steps toward breast health, and more.
"Wisdom & Wine" co-chairs Lynn Halpern and Sandy Samberg said that they are pleased to have such a prominent expert in their community. "As a Rye mother of four and a radiologist who specializes in the early diagnosis of breast cancer, Dr. Giess is the perfect 'resident expert' for our Wisdom & Wine fundraiser," said Samberg.
"She not only edcucated the attendees but did so in a relaxed and accessible manner that was both comprehensive and understandable. Attendees felt it was an incredibly empowering experience," Halpern added.
Dr. Giess added that education is the key to proper breast care. "The more educated women are about their breast health, the better chance they will have to detect any abnormalities early and seek the most appropriate medical help."
After her presentation, Dr. Giess and attendees enjoyed wine and dessert while discussing similar topics in a more casual setting. Funds raised at the event go to the Avon Foundation Breast Cancer Crusade, a 501(c) (3) public charity whose mission is to provide access to care and find a cure for breast cancer. It helps those touched by the disease today while seeking to eradicate it tomorrow. Grants are awarded to organizations ranging from leading cancer centers to local community-based breast health programs, with a special focus on the medically underserved.
Mira Women's Imaging is located at 600 Mamaroneck Ave., Suite 102, Harrison, NY 10528. For additional information, call 914.468.1000, email info(at)mirawomensimaging.com or visit www.mirawomensimaging.com.
The Sole Ryeders team was established in 2007. The team, consisting of 35 women mostly from Rye, participated in the 2007 Avon Walk for Breast Cancer and raised over $130,000 for the cause. Team leaders hope to exceed that amount in 2008. Each member commits to raising a minimum of $1,800 and walking up to 40 miles throughout New York City. The Walk takes place over two days, and most of the walkers camp out at the Wellness Village on the eve of the second day. For more information about Sole Ryeders & Friends, please email soleryeders@gmail.com.
About Mira Women's Imaging: Mira Women's Imaging is a state-of-the-art breast health facility offering mammography, breast ultrasound, DXA scans, and diagnostic care in a setting that is comfortable and private. Founder and director Dr. Catherine Giess is a fellowship-trained radiologist and a regional breast health expert with over 12 years of clinical experience in breast imaging and minimally-invasive diagnostic procedures. For more information, visit www.mirawomensimaging.com.
Harrison and Rye, NY (PRWEB) June 18, 2008 -- Dr. Catherine Giess, founder and director of Harrison-based Mira Women's Imaging, recently addressed more than 120 women, including Sole Ryeders & Friends, at the Wainwright House in Rye about breast cancer. Sole Ryeders & Friends, which was established in Rye, NY, is a team of women who will participate in the 40-mile Avon Walk for Breast Cancer in October for the second consecutive year.
More than 120 women attended the "Wisdom & Wine" Breast Cancer Awareness Fundraiser, where they learned about the different stages of breast cancer and corresponding survival rates; breast cancer risk factors; signs of breast cancer on mammography, ultrasound and MRI; the benefits of digital mammography; biopsy techniques; breast pain and lumps; the breast cancer gene; proactive steps toward breast health, and more.
"Wisdom & Wine" co-chairs Lynn Halpern and Sandy Samberg said that they are pleased to have such a prominent expert in their community. "As a Rye mother of four and a radiologist who specializes in the early diagnosis of breast cancer, Dr. Giess is the perfect 'resident expert' for our Wisdom & Wine fundraiser," said Samberg.
"She not only edcucated the attendees but did so in a relaxed and accessible manner that was both comprehensive and understandable. Attendees felt it was an incredibly empowering experience," Halpern added.
Dr. Giess added that education is the key to proper breast care. "The more educated women are about their breast health, the better chance they will have to detect any abnormalities early and seek the most appropriate medical help."
After her presentation, Dr. Giess and attendees enjoyed wine and dessert while discussing similar topics in a more casual setting. Funds raised at the event go to the Avon Foundation Breast Cancer Crusade, a 501(c) (3) public charity whose mission is to provide access to care and find a cure for breast cancer. It helps those touched by the disease today while seeking to eradicate it tomorrow. Grants are awarded to organizations ranging from leading cancer centers to local community-based breast health programs, with a special focus on the medically underserved.
Mira Women's Imaging is located at 600 Mamaroneck Ave., Suite 102, Harrison, NY 10528. For additional information, call 914.468.1000, email info(at)mirawomensimaging.com or visit www.mirawomensimaging.com.
The Sole Ryeders team was established in 2007. The team, consisting of 35 women mostly from Rye, participated in the 2007 Avon Walk for Breast Cancer and raised over $130,000 for the cause. Team leaders hope to exceed that amount in 2008. Each member commits to raising a minimum of $1,800 and walking up to 40 miles throughout New York City. The Walk takes place over two days, and most of the walkers camp out at the Wellness Village on the eve of the second day. For more information about Sole Ryeders & Friends, please email soleryeders@gmail.com.
About Mira Women's Imaging: Mira Women's Imaging is a state-of-the-art breast health facility offering mammography, breast ultrasound, DXA scans, and diagnostic care in a setting that is comfortable and private. Founder and director Dr. Catherine Giess is a fellowship-trained radiologist and a regional breast health expert with over 12 years of clinical experience in breast imaging and minimally-invasive diagnostic procedures. For more information, visit www.mirawomensimaging.com.
Subscribe to:
Posts (Atom)
